Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
13 janv. 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
12 janv. 2022 06h00 HE
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
15 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
10 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
IMM-124E – Demonstrates Antiviral T-Cell Immunity
08 oct. 2021 06h00 HE
|
Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
Immuron Director resignation
23 sept. 2021 23h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron planned Acquisition of R&D Vaccine Company
23 sept. 2021 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Innovation Metals Corp. Successfully Completes Initial Extraction-Rate Testing of the RapidSX™ Technology for Rare-Earth Elements Separation
06 juil. 2021 09h50 HE
|
Innovation Metals Corp.
TORONTO, July 06, 2021 (GLOBE NEWSWIRE) -- Innovation Metals Corp. (“IMC” or the “Company”) is pleased to announce the successful completion of initial extraction-rate testing of its proprietary...
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
13 mai 2021 06h00 HE
|
Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
Innovation Metals Corp. Announces Execution of RapidSX™ Separation Technology Testing Agreement with Rare-Earth Producer
04 mai 2021 10h04 HE
|
Innovation Metals Corp.
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Innovation Metals Corp. (“IMC” or the “Company”) is pleased to announce the execution of a binding Technology Testing Agreement (“TTA”) with a leading,...